Illustrative image – not actual.The Cabinet Committee on Economic Affairs (CCEA) has approved Glenmark and Aurobindo's foreign investment proposals, worth Rs 4,187 crore.
In February, the Foreign Investment Promotion Board had referred the proposals to CCEA for clearance as each of them exceeded its clearance limit of Rs 1,200 crore.
Mumbai-based Glenmark Pharmaceuticals had sought to raise the cap of foreign institutional investor holding to 49 per cent from present 35.07 per cent. The move will facilitate the Glenmark’s bringing in Rs 2,022 crore of foreign funds into the country.
On the other hand, Hyderabad-based Aurobindo Pharma proposed to bring in Rs 2,165 crore worth foreign investments by Qualified Institutional Buyers.
Both the companies are required to continue to produce medicines under the National List of Essential Medicines (NLEM) at the same levels as they had been doing in the past.They are also required to maintain R&D expenditure at the maximum levels incurred in the past three years and to provide complete information regarding transfer of technology that has been done.
